vs
Side-by-side financial comparison of Cardio Diagnostics Holdings, Inc. (CDIO) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($699.9M vs $3.6K, roughly 196877.6× Cardio Diagnostics Holdings, Inc.). On growth, QuidelOrtho Corp posted the faster year-over-year revenue change (-3.7% vs -21.2%). Cardio Diagnostics Holdings, Inc. produced more free cash flow last quarter ($-5.9M vs $-94.7M). Over the past eight quarters, QuidelOrtho Corp's revenue compounded faster (-2.9% CAGR vs -52.8%).
Cardio Diagnostics Holdings, Inc. is a precision cardiovascular healthcare company that develops and commercializes integrated genetic and epigenetic diagnostic tests for early detection of coronary heart disease, heart failure, and other cardiovascular conditions. It primarily serves healthcare providers, clinical laboratories, and patients across the United States, focusing on delivering accessible, personalized cardiovascular care solutions.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
CDIO vs QDEL — Head-to-Head
Income Statement — Q4 2025 vs Q3 2026
| Metric | | |
|---|---|---|
| Revenue | $3.6K | $699.9M |
| Net Profit | — | $-733.0M |
| Gross Margin | — | — |
| Operating Margin | — | -100.7% |
| Net Margin | — | -104.7% |
| Revenue YoY | -21.2% | -3.7% |
| Net Profit YoY | 3.6% | -3583.4% |
| EPS (diluted) | — | $-10.78 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.6K | — | ||
| Q3 25 | $2.9K | $699.9M | ||
| Q2 25 | $7.5K | $613.9M | ||
| Q1 25 | $940 | $692.8M | ||
| Q4 24 | $4.5K | $707.8M | ||
| Q3 24 | $6.6K | $727.1M | ||
| Q2 24 | $7.9K | $637.0M | ||
| Q1 24 | $15.9K | $711.0M |
| Q4 25 | — | — | ||
| Q3 25 | $-1.7M | $-733.0M | ||
| Q2 25 | $-1.7M | $-255.4M | ||
| Q1 25 | $-1.6M | $-12.7M | ||
| Q4 24 | — | $-178.4M | ||
| Q3 24 | $-1.4M | $-19.9M | ||
| Q2 24 | $-1.3M | $-147.7M | ||
| Q1 24 | $-4.2M | $-1.7B |
| Q4 25 | — | — | ||
| Q3 25 | -59950.9% | -100.7% | ||
| Q2 25 | -22457.5% | -29.4% | ||
| Q1 25 | -173463.8% | 4.7% | ||
| Q4 24 | — | -14.2% | ||
| Q3 24 | -21412.9% | 2.1% | ||
| Q2 24 | -16295.6% | -18.4% | ||
| Q1 24 | -26105.3% | -247.3% |
| Q4 25 | — | — | ||
| Q3 25 | -60053.8% | -104.7% | ||
| Q2 25 | -22517.7% | -41.6% | ||
| Q1 25 | -173943.0% | -1.8% | ||
| Q4 24 | — | -25.2% | ||
| Q3 24 | -21467.6% | -2.7% | ||
| Q2 24 | -16365.9% | -23.2% | ||
| Q1 24 | -26140.0% | -239.9% |
| Q4 25 | — | — | ||
| Q3 25 | $-0.98 | $-10.78 | ||
| Q2 25 | $-0.97 | $-3.77 | ||
| Q1 25 | $-0.97 | $-0.19 | ||
| Q4 24 | — | $-2.54 | ||
| Q3 24 | $-1.73 | $-0.30 | ||
| Q2 24 | $-1.71 | $-2.20 | ||
| Q1 24 | $-5.93 | $-25.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $98.1M |
| Total DebtLower is stronger | — | $2.5B |
| Stockholders' EquityBook value | $7.0M | $2.0B |
| Total Assets | $7.8M | $5.7B |
| Debt / EquityLower = less leverage | — | 1.23× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $98.1M | ||
| Q2 25 | — | $151.7M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $98.3M | ||
| Q3 24 | — | $143.7M | ||
| Q2 24 | — | $107.0M | ||
| Q1 24 | — | $78.5M |
| Q4 25 | — | — | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
| Q4 25 | $7.0M | — | ||
| Q3 25 | $8.2M | $2.0B | ||
| Q2 25 | $9.7M | $2.8B | ||
| Q1 25 | $11.4M | $3.0B | ||
| Q4 24 | $9.6M | $3.0B | ||
| Q3 24 | $3.7M | $3.2B | ||
| Q2 24 | $3.1M | $3.2B | ||
| Q1 24 | $3.0M | $3.3B |
| Q4 25 | $7.8M | — | ||
| Q3 25 | $8.8M | $5.7B | ||
| Q2 25 | $10.4M | $6.4B | ||
| Q1 25 | $12.3M | $6.5B | ||
| Q4 24 | $10.6M | $6.4B | ||
| Q3 24 | $4.5M | $6.8B | ||
| Q2 24 | $4.0M | $6.7B | ||
| Q1 24 | $4.3M | $6.7B |
| Q4 25 | — | — | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.68× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.7M | $-45.5M |
| Free Cash FlowOCF − Capex | $-5.9M | $-94.7M |
| FCF MarginFCF / Revenue | -166361.5% | -13.5% |
| Capex IntensityCapex / Revenue | 5269.1% | 7.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-10.5M | $-153.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.7M | — | ||
| Q3 25 | $-1.4M | $-45.5M | ||
| Q2 25 | $-1.6M | $-46.8M | ||
| Q1 25 | $-1.4M | $65.6M | ||
| Q4 24 | $-5.0M | $63.7M | ||
| Q3 24 | $-1.2M | $117.9M | ||
| Q2 24 | $-1.2M | $-97.9M | ||
| Q1 24 | $-1.2M | $-700.0K |
| Q4 25 | $-5.9M | — | ||
| Q3 25 | $-1.6M | $-94.7M | ||
| Q2 25 | $-1.6M | $-84.3M | ||
| Q1 25 | $-1.4M | $9.4M | ||
| Q4 24 | $-5.2M | $16.5M | ||
| Q3 24 | $-1.2M | $71.4M | ||
| Q2 24 | $-1.4M | $-133.2M | ||
| Q1 24 | $-1.3M | $-66.8M |
| Q4 25 | -166361.5% | — | ||
| Q3 25 | -54509.7% | -13.5% | ||
| Q2 25 | -21273.1% | -13.7% | ||
| Q1 25 | -149562.6% | 1.4% | ||
| Q4 24 | -115422.6% | 2.3% | ||
| Q3 24 | -17942.3% | 9.8% | ||
| Q2 24 | -17513.3% | -20.9% | ||
| Q1 24 | -7866.9% | -9.4% |
| Q4 25 | 5269.1% | — | ||
| Q3 25 | 5703.5% | 7.0% | ||
| Q2 25 | 250.1% | 6.1% | ||
| Q1 25 | 615.6% | 8.1% | ||
| Q4 24 | 4759.9% | 6.7% | ||
| Q3 24 | 353.3% | 6.4% | ||
| Q2 24 | 2133.4% | 5.5% | ||
| Q1 24 | 125.5% | 9.3% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CDIO
Segment breakdown not available.
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
